J.B. Chemicals & Pharmaceuticals Lt
₹2,412.25₹0.00 (0.0%)
Last close · Data as of Jul 17, 2026
- Market cap
- ₹29,217 Cr
- P/E
- 41.5x
- EV / EBITDA
- 32.1x
- Revenue
- ₹3,723 Cr
- Net margin
- 16.5%
- ROCE
- 27.1%
Price chart
Technical chartScreen technicals →+45.0% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- +9.8%
- 3M
- +20.8%
- 6M
- +28.2%
- 1Y
- +45.0%
- 5Y
- +183.0%
52-week range
Day change ₹0.00 (0.0%) from ₹2,412 to ₹2,412 · Last close Jul 17, 2026
Best weekday to invest, historically
The same weekly amount in JBCHEPHARM, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Strong 5-year net profit CAGR of 15.2%
Concerns0
Rule-based from financial data. Not advice.
About the company
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI.
Read moreShow less
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, the company offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. It provides its products to gastroenterology, anti-infectives, wound care, neonatology and pediatrics, gynaecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.
- Sector
- Healthcare
- Shares outstanding
- 15.6 Cr shares
- ISIN
- INE572A01036
- BSE code
- 506943
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹29,217 Cr
- P/E
- 41.5x
- P/B
- 7.9x
- EV / EBITDA
- 32.1x
- EV / Sales
- 8.9x
- P/S
- 8.9x
- Earnings yield
- 2.4%
- 52-week high
- ₹2,505.60
- 52-week low
- ₹1,608.35
Profitability
- Operating margin
- 26.7%
- Net margin
- 16.5%
- EBITDA margin
- 27.7%
- ROE
- 18.8%
- ROCE
- 27.1%
- ROA
- 13.9%
- Dividend payout
- 35.0%
- Tax rate
- 26.0%
- Other income, % of PBT
- 4.6%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹3,723 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 12.9%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 15.0%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹914 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 35.6%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 20.3%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 15.2%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹789 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 25.4%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹20.0 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 12.8%
Solvency and efficiency
- Current ratio
- 2.86
- Debt / Equity
- 0.12
- Debt / Assets
- 0.09
- Debt / EBITDA
- 0.39
- Interest coverage
- 21.46
- Financial leverage
- 1.36
- CFO / Net profit
- 1.45
- Cash / Market cap
- 4.7%
- Cash per share
- ₹88.34
- Asset turnover
- 0.84
- Fixed asset turnover
- 1.71
- Capital intensity
- 0.58
- Debtor days
- 69 days
- Inventory turnover
- 2.40
- Cash conversion cycle
- 112 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹18 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹2,705 Cr |
| Sales | Operating profit | ₹1,018 Cr |
| Operating profit | Interest | ₹9 Cr |
| Operating profit | Depreciation | ₹166 Cr |
| Operating profit | Profit before tax | ₹843 Cr |
| Other income | Profit before tax | ₹35 Cr |
| Profit before tax | Tax and other | ₹224 Cr |
| Profit before tax | Net profit | ₹653 Cr |
Revenue and net profit
Revenue grew 12.9% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹1,892 Cr | ₹447 Cr |
| FY2022 | ₹2,190 Cr | ₹361 Cr |
| FY2023 | ₹2,884 Cr | ₹389 Cr |
| FY2024 | ₹3,299 Cr | ₹543 Cr |
| FY2025 | ₹3,723 Cr | ₹653 Cr |
Cash flows
FY2025: ₹884 Cr from operations, ₹594 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹335 Cr | ₹104 Cr |
| FY2022 | ₹147 Cr | ₹151 Cr |
| FY2023 | ₹629 Cr | -₹327 Cr |
| FY2024 | ₹789 Cr | ₹377 Cr |
| FY2025 | ₹884 Cr | ₹594 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹3,723 Cr+12.9%1Y
- Net profit
- ₹653 Cr+20.3%1Y
- Cash from operations
- ₹884 Cr
- Free cash flow
- ₹594 Cr+57.6%1Y
- Revenue CAGR, 5Y
- 15.0%
- EBITDA CAGR, 5Y
- 17.6%
- Net profit CAGR, 5Y
- 15.2%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹3,723 Cr | ₹1,018 Cr | — | ₹653 Cr | ₹884 Cr | ₹594 Cr | 19.3% | +12.9% | +20.3% |
Monthly returns
Month-by-month returns of JBCHEPHARM across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹4,178 Cr |
| Equity capital | ₹16 Cr |
| Reserves | ₹3,362 Cr |
| Borrowings | ₹12 Cr |
| Other liabilities | ₹788 Cr |
| Assets | ₹4,178 Cr |
| Fixed assets | ₹1,883 Cr |
| Capital work in progress | ₹62 Cr |
| Investments | ₹488 Cr |
| Other assets | ₹1,745 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
JBCHEPHARM trades at 41.5x earnings against a peer median of 52.6x (a 21% discount).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| J.B. Chemicals & Pharmaceuticals LtJBCHEPHARMthis companyP/E ↓ discount | ₹29,217 Cr | 41.5x | 7.9x | 18.8% | 32.1x |
| Ajanta Pharma Ltd.AJANTPHARM | ₹34,058 Cr | 35.8x | 8.3x | 23.6% | 27.3x |
| Global Health LimitedMEDANTA | ₹31,404 Cr | 59.8x | 8.3x | 16.0% | 37.3x |
| Aster DM Healthcare LimitedASTERDM | ₹31,356 Cr | 92.8x | 7.1x | 5.4% | 78.2x |
| Emcure Pharmaceuticals LimitedEMCURE | ₹29,399 Cr | 67.9x | 9.1x | 8.3% | 53.5x |
| Gland Pharma LimitedGLAND | ₹28,321 Cr | 24.5x | 2.8x | 11.6% | 17.3x |
| Syngene International LimitedSYNGENE | ₹25,375 Cr | 58.0x | 5.5x | 11.1% | 26.5x |
| Krishna Institute of Medical Sciences LimitedKIMS | ₹24,919 Cr | 87.7x | 10.9x | 12.6% | 65.6x |
| Pine Labs LimitedPINELABS | ₹24,711 Cr | 442.0x | — | -9.1% | 164.0x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
JBCHEPHARM since 1 January, against earlier years.
Historical volatility
JBCHEPHARM's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 29.0% |
| FY2022 | 23.0% |
| FY2023 | 23.0% |
| FY2024 | 27.0% |
| FY2025 | 27.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹3,723 Cr |
| Costs | |
| Interest | ₹9 Cr |
| Expenses | ₹2,705 Cr |
| Operating profitOperating Profit | ₹1,018 Cr |
| Other income and charges | |
| Profit before tax | ₹877 Cr |
| Tax | |
| Net profitNet Profit | ₹653 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹4,178 Cr |
| Equity capitalEquity Capital | ₹16 Cr |
| Reserves | ₹3,362 Cr |
| Borrowings | ₹12 Cr |
| Other liabilitiesOther Liabilities | ₹788 Cr |
| AssetsTotal Assets | ₹4,178 Cr |
| Fixed assetsFixed Assets | ₹1,883 Cr |
| Capital work in progressCWIP | ₹62 Cr |
| Investments | ₹488 Cr |
| Other assetsOther Assets | ₹1,745 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹884 Cr |
| Investing cash flowCash from Investing Activity | -₹290 Cr |
| Financing cash flowCash from Financing Activity | -₹574 Cr |
| Change in cashNet Cash Flow | ₹20 Cr |
Learn while you research
Academy chapters picked for J.B. Chemicals & Pharmaceuticals Lt and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 41.5, learn when high multiples are justified.6 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read